Invest in

Drug-Patent Cliffs

22.3%
1.6%
0.7%

Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See more
22.3%
1.6%
0.7%
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
Motif Index 1 YR Return
Drug-Patent Cliffs Benchmark
With this Motif, you can buy the following basket of stocks for just $9.95:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
100% Generic Drugs 14.4%
20.5% Dr. Reddy's Laboratories Ltd RDY 1.5%
19.6% Taro Pharmaceutical Industries Ltd. TARO 27.9%
19.3% Mylan N.V. MYL 24.8%
9.8% Abbott Laboratories ABT 4.2%
9.0% The Medicines Company MDCO 16.9%
6.4% Akorn Inc. AKRX 19.2%
5.8% Mallinckrodt plc MNK 18.1%
5.0% Impax Laboratories Inc. IPXL 64.4%
2.2% Lannett Co Inc LCI 39.6%
1.6% Cambrex Corporation CBM 37.1%
0.8% Endo International PLC ENDP 75.0%

Quotes delayed 15 mins. Currently Jan 17, 2017 4:19:52 PM. Fields are marked with -- when data is unavailable.